SOSAFE-GMBH
7.2.2024 09:01:27 CET | Business Wire | Press release
SoSafe, Europe’s leading vendor for security awareness, behavior, and culture change, today announced the appointment of Andrew Rose as its new Chief Security Officer (CSO). With a wealth of experience in the industry, Rose is a highly accomplished cyber security executive with a strong focus on the people-centric aspects of cyber security.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240207094549/en/
Andrew Rose appointed as new Chief Security Officer at leading security awareness vendor SoSafe (Photo: Business Wire)
In his role as CSO, Rose will focus on driving SoSafe’s vision to strengthen digital self-defense worldwide and help customers transform their security culture. He’ll also bring hands-on experience, knowledge, and perspective in managing risk and improving cyber security posture across complex enterprises.
Recognized for his outstanding contributions to the field, Rose was awarded the prestigious title of 'European CISO of the Year 2018' at the SC Awards, and has been a part of the CSO30 every year since its inception in 2020. Across his career, Rose has transformed security management for multiple major organizations in the legal, aviation, technology, and finance sectors.
Notably, Rose held the position as Resident CISO at Proofpoint Inc., where he helped customers enhance their security practices, cultivated a community of CISOs and represented the brand externally. Prior to that, he oversaw the cyber security of UK airspace traffic at NATS and managed the secure processing of trillions of pounds in transfers at Vocalink, a Mastercard company. He also worked at Forrester Research, where he was Principal Analyst covering the awareness and culture change space and developed influential models for the security awareness industry. In 2015, when Rose implemented the models he had designed at Forrester, he was awarded ‘UK Awareness Campaign of the Year’ at the UK Cyber Security Awards. Rose also has an established record in the legal sector with over a decade as CISO at 'magic circle' firms Clifford Chance LLP and Allen & Overy LLP.
Niklas Hellemann, Psychologist and CEO of SoSafe, remarked: "Andrew’s expertise is a perfect match for our mission at SoSafe. In an era where AI-powered cyber threats are escalating, Andrew's extensive industry experience is invaluable in leading our efforts to be the global industry leader in fortifying the human aspect of cyber security.”
Rose's decision to join SoSafe was driven by the company's unwavering focus on addressing the critical problem of the underestimated human factor in cyber security. “There is a huge imbalance in focus as the biggest part of security budgets are dedicated to security technology while according to the World Economic Forum, 95% of cyber threats have a human element involved. SoSafe’s commitment to strengthening the human factor, coupled with their innovative use of behavioral science and technology, aligns perfectly with my vision.”
“SoSafe’s approach to security awareness is unique in the industry: Having a CEO with a background in psychology means that the human-centric perspective is deeply rooted in their DNA. They focus on behavioral science to tackle the problem and then use technology to enable the solution”, Rose stated.
By joining SoSafe, Andrew Rose will further strengthen the company's position as a leader in the industry. With his track record of success and commitment to driving secure behavior in organizations, Andrew Rose is poised to make a significant contribution to the company's ongoing mission of strengthening digital self-defense.
About SoSafe
SoSafe empowers organizations to build a security culture and mitigate risk with its GDPR-compliant awareness programs. The company was founded in Cologne, Germany, in 2018 by Dr Niklas Hellemann, Lukas Schaefer, and Felix Schuerholz. Today, it serves more than 4500 customers worldwide and is the market leader in security awareness and training in the DACH region. As one of the leading second-generation awareness platforms, they are powered by behavioral science and smart algorithms and focus on user engagement and the needs of the customer. In doing so, SoSafe delivers engaging, personalized learning experiences and smart attack simulations that turn employees into active assets against online threats. The SoSafe team consists of more than 370 employees at seven locations: Cologne (headquarters), Amsterdam, Berlin, Lisbon, London, Munich, and Paris.
Website: www.sosafe-awareness.com/
LinkedIn: www.linkedin.com/company/sosafe-cyber-security/mycompany/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240207094549/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
